Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro

Vamsi P. Guntur, J. Clifford Waldrep, Jennifer J. Guo, Kim Selting, Rajiv Dhand

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aim: To determine whether increasing p53 protein levels confers enhanced chemosensitivity in non-small cell lung cancer (NSCLC). Materials and Methods: Three NSCLC cell lines, with different endogenous p53 expression, were transfected with wild-type p53 (wt-p53) or CD-1 (truncated wt-p53) genes. Cells were subsequently treated with cisplatin (CDDP) or paclitaxel (PAX). Cell viability was measured using Alamar Blue Assay. Results: Cells transfected with CD-1 expressed 13-38% higher levels of p53 protein compared to cells transfected with the wt-p53 gene, despite their baseline endogenous levels. CD-1-transfected cells also had higher cell death when treated with CDDP (p<0.05) or PAX, exhibiting 30-60% higher death rates than cells transfected with the wt-p53 gene and 130-160% higher than untransfected cells. A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R2 for CDDP=0.823; R2 for PAX=0.909; p<0.001). Conclusion: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression.

Original languageEnglish (US)
Pages (from-to)3557-3564
Number of pages8
JournalAnticancer research
Volume30
Issue number9
StatePublished - Sep 1 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Paclitaxel
p53 Genes
Proteins
Cisplatin
TP protocol
In Vitro Techniques
Cell Survival
Cell Death
Cell Line
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. / Guntur, Vamsi P.; Waldrep, J. Clifford; Guo, Jennifer J.; Selting, Kim; Dhand, Rajiv.

In: Anticancer research, Vol. 30, No. 9, 01.09.2010, p. 3557-3564.

Research output: Contribution to journalArticle

Guntur, VP, Waldrep, JC, Guo, JJ, Selting, K & Dhand, R 2010, 'Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro', Anticancer research, vol. 30, no. 9, pp. 3557-3564.
Guntur, Vamsi P. ; Waldrep, J. Clifford ; Guo, Jennifer J. ; Selting, Kim ; Dhand, Rajiv. / Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. In: Anticancer research. 2010 ; Vol. 30, No. 9. pp. 3557-3564.
@article{de03050fe67f4964a2b4e7d9e21e2343,
title = "Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro",
abstract = "Aim: To determine whether increasing p53 protein levels confers enhanced chemosensitivity in non-small cell lung cancer (NSCLC). Materials and Methods: Three NSCLC cell lines, with different endogenous p53 expression, were transfected with wild-type p53 (wt-p53) or CD-1 (truncated wt-p53) genes. Cells were subsequently treated with cisplatin (CDDP) or paclitaxel (PAX). Cell viability was measured using Alamar Blue Assay. Results: Cells transfected with CD-1 expressed 13-38{\%} higher levels of p53 protein compared to cells transfected with the wt-p53 gene, despite their baseline endogenous levels. CD-1-transfected cells also had higher cell death when treated with CDDP (p<0.05) or PAX, exhibiting 30-60{\%} higher death rates than cells transfected with the wt-p53 gene and 130-160{\%} higher than untransfected cells. A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R2 for CDDP=0.823; R2 for PAX=0.909; p<0.001). Conclusion: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression.",
author = "Guntur, {Vamsi P.} and Waldrep, {J. Clifford} and Guo, {Jennifer J.} and Kim Selting and Rajiv Dhand",
year = "2010",
month = "9",
day = "1",
language = "English (US)",
volume = "30",
pages = "3557--3564",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro

AU - Guntur, Vamsi P.

AU - Waldrep, J. Clifford

AU - Guo, Jennifer J.

AU - Selting, Kim

AU - Dhand, Rajiv

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Aim: To determine whether increasing p53 protein levels confers enhanced chemosensitivity in non-small cell lung cancer (NSCLC). Materials and Methods: Three NSCLC cell lines, with different endogenous p53 expression, were transfected with wild-type p53 (wt-p53) or CD-1 (truncated wt-p53) genes. Cells were subsequently treated with cisplatin (CDDP) or paclitaxel (PAX). Cell viability was measured using Alamar Blue Assay. Results: Cells transfected with CD-1 expressed 13-38% higher levels of p53 protein compared to cells transfected with the wt-p53 gene, despite their baseline endogenous levels. CD-1-transfected cells also had higher cell death when treated with CDDP (p<0.05) or PAX, exhibiting 30-60% higher death rates than cells transfected with the wt-p53 gene and 130-160% higher than untransfected cells. A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R2 for CDDP=0.823; R2 for PAX=0.909; p<0.001). Conclusion: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression.

AB - Aim: To determine whether increasing p53 protein levels confers enhanced chemosensitivity in non-small cell lung cancer (NSCLC). Materials and Methods: Three NSCLC cell lines, with different endogenous p53 expression, were transfected with wild-type p53 (wt-p53) or CD-1 (truncated wt-p53) genes. Cells were subsequently treated with cisplatin (CDDP) or paclitaxel (PAX). Cell viability was measured using Alamar Blue Assay. Results: Cells transfected with CD-1 expressed 13-38% higher levels of p53 protein compared to cells transfected with the wt-p53 gene, despite their baseline endogenous levels. CD-1-transfected cells also had higher cell death when treated with CDDP (p<0.05) or PAX, exhibiting 30-60% higher death rates than cells transfected with the wt-p53 gene and 130-160% higher than untransfected cells. A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R2 for CDDP=0.823; R2 for PAX=0.909; p<0.001). Conclusion: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression.

UR - http://www.scopus.com/inward/record.url?scp=77958595596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958595596&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 3557

EP - 3564

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -